Literature DB >> 20214808

Automated evaluation of autoantibodies on human epithelial-2 cells as an approach to standardize cell-based immunofluorescence tests.

Karl Egerer1, Dirk Roggenbuck, Rico Hiemann, Max-Georg Weyer, Thomas Büttner, Boris Radau, Rosemarie Krause, Barbara Lehmann, Eugen Feist, Gerd-Rüdiger Burmester.   

Abstract

INTRODUCTION: Analysis of autoantibodies (AAB) by indirect immunofluorescence (IIF) is a basic tool for the serological diagnosis of systemic rheumatic disorders. Automation of autoantibody IIF reading including pattern recognition may improve intra- and inter-laboratory variability and meet the demand for cost-effective assessment of large numbers of samples. Comparing automated and visual interpretation, the usefulness for routine laboratory diagnostics was investigated.
METHODS: Autoantibody detection by IIF on human epithelial-2 (HEp-2) cells was conducted in a total of 1222 consecutive sera of patients with suspected systemic rheumatic diseases from a university routine laboratory (n = 924) and a private referral laboratory (n = 298). IIF results from routine diagnostics were compared with a novel automated interpretation system.
RESULTS: Both diagnostic procedures showed a very good agreement in detecting AAB (kappa = 0.828) and differentiating respective immunofluorescence patterns. Only 98 (8.0%) of 1222 sera demonstrated discrepant results in the differentiation of positive from negative samples. The contingency coefficients of chi-square statistics were 0.646 for the university laboratory cohort with an agreement of 93.0% and 0.695 for the private laboratory cohort with an agreement of 90.6%, P < 0.0001, respectively. Comparing immunofluorescence patterns, 111 (15.3%) sera yielded differing results.
CONCLUSIONS: Automated assessment of AAB by IIF on HEp-2 cells using an automated interpretation system is a reliable and robust method for positive/negative differentiation. Employing novel mathematical algorithms, automated interpretation provides reproducible detection of specific immunofluorescence patterns on HEp-2 cells. Automated interpretation can reduce drawbacks of IIF for AAB detection in routine diagnostics providing more reliable data for clinicians.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20214808      PMCID: PMC2888187          DOI: 10.1186/ar2949

Source DB:  PubMed          Journal:  Arthritis Res Ther        ISSN: 1478-6354            Impact factor:   5.156


  36 in total

1.  Multicenter evaluation study on a new HEp2 ANA screening enzyme immune assay.

Authors:  P M Bayer; S Bauerfeind; J Bienvenu; N Fabien; P C Frei; B Gilburd; K G Heide; M Hoier-Madsen; P L Meroni; J C Monier; G Monneret; P Panzeri; Y Shoenfeld; F Spertini; A Wiik
Journal:  J Autoimmun       Date:  1999-08       Impact factor: 7.094

2.  Detection and identification of antinuclear antibodies (ANA) in a large and consecutive cohort of serum samples referred for ANA testing.

Authors:  I Peene; L Meheus; E M Veys; F De Keyser
Journal:  Ann Rheum Dis       Date:  2001-12       Impact factor: 19.103

Review 3.  Antinuclear antibodies specific for primary biliary cirrhosis.

Authors:  Howard J Worman; Jean Claude Courvalin
Journal:  Autoimmun Rev       Date:  2003-06       Impact factor: 9.754

4.  Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing.

Authors:  Daniel H Solomon; Arthur J Kavanaugh; Peter H Schur
Journal:  Arthritis Rheum       Date:  2002-08

5.  Mining knowledge for HEp-2 cell image classification.

Authors:  Petra Perner; Horst Perner; Bernd Müller
Journal:  Artif Intell Med       Date:  2002 Sep-Oct       Impact factor: 5.326

6.  Utility of age, gender, ANA titer and pattern as predictors of anti-ENA and -dsDNA antibodies.

Authors:  Insoo Kang; Robyn Siperstein; Tim Quan; Mary Lou Breitenstein
Journal:  Clin Rheumatol       Date:  2004-12       Impact factor: 2.980

Review 7.  Anti-nuclear autoantibodies: clinical utility for diagnosis, prognosis, monitoring, and planning of treatment strategy in systemic immunoinflammatory diseases.

Authors:  A S Wiik
Journal:  Scand J Rheumatol       Date:  2005 Jul-Aug       Impact factor: 3.641

Review 8.  From ANA to ENA: how to proceed?

Authors:  J G M C Damoiseaux; J W Cohen Tervaert
Journal:  Autoimmun Rev       Date:  2005-06-13       Impact factor: 9.754

9.  Evaluation of the BioPlex 2200 ANA screen: analysis of 510 healthy subjects: incidence of natural/predictive autoantibodies.

Authors:  O Shovman; B Gilburd; O Barzilai; E Shinar; B Larida; G Zandman-Goddard; S R Binder; Y Shoenfeld
Journal:  Ann N Y Acad Sci       Date:  2005-06       Impact factor: 5.691

10.  Exposure of HEp-2 cells to stress conditions influences antinuclear antibody reactivity.

Authors:  Liping Du; Sachiko Fukushima; Annahita Sallmyr; Rolf Manthorpe; Anders Bredberg
Journal:  Clin Diagn Lab Immunol       Date:  2002-03
View more
  36 in total

1.  A fully automated IIF system for the detection of antinuclear antibodies and antineutrophil cytoplasmic antibodies.

Authors:  O Shovman; N Agmon-Levin; B Gilburd; T Martins; A Petzold; T Matthias; Y Shoenfeld
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

2.  Clinical performance evaluation of a novel, automated chemiluminescent immunoassay, QUANTA Flash CTD Screen Plus.

Authors:  Chelsea Bentow; Gabriella Lakos; Rachel Rosenblum; Cassandra Bryant; Andrea Seaman; Michael Mahler
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

3.  Antinuclear antibodies detection: A comparative study between automated recognition and conventional visual interpretation.

Authors:  ZhiYan Li; RuiLin Han; ZhenLin Yan; LiJuan Li; ZhenRu Feng
Journal:  J Clin Lab Anal       Date:  2018-07-20       Impact factor: 2.352

4.  [Rheumatoid factor or antinuclear antibodies as incidental finding].

Authors:  R Biesen; G-R Burmester; F Hiepe
Journal:  Internist (Berl)       Date:  2014-10       Impact factor: 0.743

5.  The burden of the variability introduced by the HEp-2 assay kit and the CAD system in ANA indirect immunofluorescence test.

Authors:  M Infantino; F Meacci; V Grossi; M Manfredi; M Benucci; M Merone; P Soda
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

6.  A novel automated indirect immunofluorescence autoantibody evaluation.

Authors:  Shaye Kivity; Boris Gilburd; Nancy Agmon-Levin; Marina Garcia Carrasco; Yaron Tzafrir; Yael Sofer; Matilda Mandel; Thomas Buttner; Dirk Roggenbuck; Marco Matucci-Cerinic; Katalin Danko; Marcos López Hoyos; Yehuda Shoenfeld
Journal:  Clin Rheumatol       Date:  2011-11-05       Impact factor: 2.980

Review 7.  Recent Approaches To Optimize Laboratory Assessment of Antinuclear Antibodies.

Authors:  Anne E Tebo
Journal:  Clin Vaccine Immunol       Date:  2017-12-05

8.  In-vitro and in-vivo imaging of prostate tumor using NaYF4: Yb, Er up-converting nanoparticles.

Authors:  Yongjiang Yu; Tao Huang; Yu Wu; Xiaorong Ma; Guopeng Yu; Jun Qi
Journal:  Pathol Oncol Res       Date:  2013-11-14       Impact factor: 3.201

9.  Centromere and cytoplasmic staining pattern recognition: a local approach.

Authors:  Giulio Iannello; Leonardo Onofri; Paolo Soda
Journal:  Med Biol Eng Comput       Date:  2013-07-23       Impact factor: 2.602

10.  Adhesion of human and animal Escherichia coli strains in association with their virulence-associated genes and phylogenetic origins.

Authors:  Ulrike Frömmel; Werner Lehmann; Stefan Rödiger; Alexander Böhm; Jörg Nitschke; Jörg Weinreich; Julia Groß; Dirk Roggenbuck; Olaf Zinke; Hermann Ansorge; Steffen Vogel; Per Klemm; Thomas Wex; Christian Schröder; Lothar H Wieler; Peter Schierack
Journal:  Appl Environ Microbiol       Date:  2013-07-19       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.